| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The deuterated compound itself has no independent pharmacological target; it is chemically identical to 3-hydroxy agomelatine, which is known to act as a 5-HT2C receptor antagonist and a melatonin (MT1/MT2) receptor agonist (although less potent than the parent drug). Specifically, 3-hydroxy agomelatine (unlabeled) binds to 5-HT2C receptors with an IC50 of 3.2 uM and a Ki of 1.8 uM. It also displays partial agonist activity at MT1 and MT2 receptors. The D3 label does not alter binding affinity.
|
|---|---|
| ln Vitro |
In vitro, the unlabeled 3-hydroxy agomelatine (0.1-100 uM) inhibits 5-HT2C-mediated inositol phosphate accumulation in CHO cells expressing the receptor, with an IC50 of 1.6 uM. It also increases cAMP levels in MT1/MT2-expressing cells, but with lower efficacy than agomelatine (EC50 ≈ 100 nM vs. 10 nM). The deuterium-labeled version is not used in biological activity assays because it serves as an analytical standard. No in vitro activity data for the D3-labeled compound are available or relevant.
|
| ln Vivo |
No in vivo activity studies have been performed with the deuterated compound. The unlabeled metabolite 3-hydroxy agomelatine contributes to the overall antidepressant and chronobiotic effects of agomelatine in vivo, but it is less potent and crosses the blood-brain barrier less efficiently. In rats, intravenous administration of 3-hydroxy agomelatine (10 mg/kg) produces modest (20%) reductions in wakefulness during the dark phase, similar to agomelatine but requiring 10-fold higher dose. The D3-labeled compound is not intended for in vivo use.
|
| Enzyme Assay |
Radioligand binding assay for 5-HT2C: Membrane preparations from HEK293 cells stably expressing the human 5-HT2C receptor (20 ug protein) are incubated with 0.5 nM [3H]-mesulergine in the presence of increasing concentrations of unlabeled 3-hydroxy agomelatine (1 nM-100 uM) for 60 minutes at 37degC. Non-specific binding is determined with 10 uM mianserin. Bound radioactivity is filtered through GF/C filters and counted. Ki is calculated from IC50 using the Cheng-Prusoff equation. For the D3 compound, it is not used in such assays.
|
| Cell Assay |
Not applicable for the D3-labeled compound. For unlabeled 3-hydroxy agomelatine, a functional assay can be performed: CHO cells expressing human 5-HT2C receptor are loaded with [3H]-myo-inositol and treated with 10 uM serotonin +/- test compound for 30 minutes; inositol phosphates are extracted and counted. For the D3-labeled version, no cell-based assays are performed because it is an analytical standard.
|
| Animal Protocol |
Not applicable. The D3-labeled compound is used as an internal standard in pharmacokinetic studies of agomelatine. In such studies, animals (rats or dogs) are administered unlabeled agomelatine orally or intravenously. Blood samples are collected at time points (0-24 h), plasma is spiked with a known amount of 3-Hydroxy agomelatine D3, and the concentration of agomelatine and its metabolites are quantified by LC-MS/MS. The D3 compound itself is not dosed to animals.
|
| ADME/Pharmacokinetics |
Not applicable (not a drug). The deuterated label does not alter the pharmacokinetic properties of 3-hydroxy agomelatine. For the unlabeled metabolite, it is formed rapidly after agomelatine administration. Agomelatine has low oral bioavailability (5-10% in humans), extensive first-pass metabolism (CYP1A2 and CYP2C9), and a short elimination half-life (1-2 hours). 3-Hydroxy agomelatine is further conjugated to glucuronide before renal excretion. The D3 internal standard is used to correct for matrix effects, ion suppression, and extraction recovery in bioanalysis.
|
| Toxicity/Toxicokinetics |
No toxicity data for the D3 compound. Agomelatine (parent drug) is generally well-tolerated; common adverse effects include headache, nausea, diarrhea, and hepatotoxicity (elevated liver enzymes, rare cases of hepatitis). The metabolite 3-hydroxy agomelatine has not been associated with unique toxicities. The D3 label is non-radioactive and stable, posing no additional hazard. The compound should be handled as a chemical with potential irritancy (standard precautions).
|
| References | |
| Additional Infomation |
3-Hydroxy agomelatine D3 is a stable isotope-labeled internal standard for analytical chemistry applications, particularly in support of clinical pharmacokinetic and bioequivalence studies of agomelatine. It is not a drug, has no therapeutic use, is not approved by any regulatory agency, and has never been tested in humans as a stand-alone entity. Agomelatine (parent drug) is approved in Europe, Australia, and Asia for the treatment of major depressive disorder. The D3-labeled metabolite is sold by chemical suppliers for research use only.
|
| Molecular Formula |
C15H17NO3
|
|---|---|
| Molecular Weight |
259.300384283066
|
| Exact Mass |
262.139
|
| CAS # |
1079774-23-4
|
| Related CAS # |
3-Hydroxy agomelatine;166526-99-4
|
| PubChem CID |
145925681
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
308
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1=CC(O)=CC2C=CC(OC([H])([H])[H])=CC1=2)CNC(=O)C
|
| InChi Key |
VUBBOOVHTBZRTJ-BMSJAHLVSA-N
|
| InChi Code |
InChI=1S/C15H17NO3/c1-10(17)16-6-5-12-8-13(18)7-11-3-4-14(19-2)9-15(11)12/h3-4,7-9,18H,5-6H2,1-2H3,(H,16,17)/i2D3
|
| Chemical Name |
N-[2-[3-hydroxy-7-(trideuteriomethoxy)naphthalen-1-yl]ethyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8565 mL | 19.2827 mL | 38.5654 mL | |
| 5 mM | 0.7713 mL | 3.8565 mL | 7.7131 mL | |
| 10 mM | 0.3857 mL | 1.9283 mL | 3.8565 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
